SEC Info - Iovance Biotherapeutics, Inc. - ‘8-K’ for 3/4/24

SEC Info℠

Home

Help

Please Sign In

Iovance Biotherapeutics, Inc. – ‘8-K’ for 3/4/24

On: Monday, 3/4/24, at 8:00am ET · For: 3/4/24 · Accession #: 1104659-24-30249 · File #: 1-36860

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/04/24  Iovance Biotherapeutics, Inc.     8-K:8,9     3/04/24   11:224K                                   Toppan Merrill/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     26K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     15K 
 6: R1          Cover                                               HTML     47K 
 8: XML         IDEA XML File -- Filing Summary                      XML     11K 
11: XML         XBRL Instance -- tm247846d1_8k_htm                   XML     16K 
 7: EXCEL       IDEA Workbook of Financial Report Info              XLSX      8K 
 4: EX-101.LAB  XBRL Labels -- iova-20240304_lab                     XML     96K 
 5: EX-101.PRE  XBRL Presentations -- iova-20240304_pre              XML     64K 
 3: EX-101.SCH  XBRL Schema -- iova-20240304                         XSD     12K 
 9: JSON        XBRL Instance as JSON Data -- MetaLinks               25±    34K 
10: ZIP         XBRL Zipped Folder -- 0001104659-24-030249-xbrl      Zip     20K

Filing Submission 0001104659-24-030249 – SGML Text

Original SGML Text submitted by:	Toppan Merrill/FA (as Filing Agent)

⇓Show all <DOCUMENT> <TEXT> elements below – 224K ↑Top ↓Bottom

<SUBMISSION>
<SECRELEASE-DATETIME>		20240304-080115	 ⇐ Metadata from SEC Info (ET)
<SECWEBSITE-DATETIME>		20240304-080112	 ⇐ Metadata from SEC Info (ET)
<ACCEPTANCE-DATETIME>		20240304-080020	 ⇐ Filing accepted by SEC (ET)
<ACCESSION-NUMBER>		0001104659-24-030249
<TYPE>				8-K
<PUBLIC-DOCUMENT-COUNT>		14
<PERIOD>			20240304
<ITEMS>				8.01
<ITEMS>				9.01
<FILING-DATE>			20240304
<DATE-OF-FILING-DATE-CHANGE>	20240304

<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>		IOVANCE BIOTHERAPEUTICS, INC.
<CIK>				0001425205
<ASSIGNED-SIC>			2836
<ORGANIZATION-NAME>		03 Life Sciences
<IRS-NUMBER>			753254381  ⇒ 75-3254381
<STATE-OF-INCORPORATION>	DE
<FISCAL-YEAR-END>		1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>			8-K
<ACT>				34
<FILE-NUMBER>			001-36860
<FILM-NUMBER>			24712875
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>			825 INDUSTRIAL ROAD
<STREET2>			4TH FLOOR
<CITY>				SAN CARLOS
<STATE>				CA
<ZIP>				94070
<PHONE>				6502607120
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>			825 INDUSTRIAL ROAD
<STREET2>			4TH FLOOR
<CITY>				SAN CARLOS
<STATE>				CA
<ZIP>				94070
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>		Lion Biotechnologies, Inc.
<DATE-CHANGED>			20131015
</FORMER-COMPANY>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>		Genesis Biopharma, Inc
<DATE-CHANGED>			20100319
</FORMER-COMPANY>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>		FREIGHT MANAGEMENT CORP
<DATE-CHANGED>			20080128
</FORMER-COMPANY>
</FILER>

<DOCUMENT>
<TYPE>		8-K
<SEQUENCE>	1
<FILENAME>	tm247846d1_8k.htm
<DESCRIPTION>	FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:iova="http://lbio.com/20240304">
       Show <XBRL>: 309 lines (widest: 855 characters) - 26K bytes  
</TEXT>
</DOCUMENT>

<DOCUMENT>
<TYPE>		EX-99.1
<SEQUENCE>	2
<FILENAME>	tm247846d1_ex99-1.htm
<DESCRIPTION>	EXHIBIT 99.1
<TEXT>
<HTML>
       Show <HTML>: 171 lines (widest: 157 characters) - 14K bytes  
</TEXT>
</DOCUMENT>

<DOCUMENT>
<TYPE>		EX-101.SCH
<SEQUENCE>	3
<FILENAME>	iova-20240304.xsd
<DESCRIPTION>	XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
       Show <XBRL>: 30 lines (widest: 557 characters) - 3K bytes  
</TEXT>
</DOCUMENT>

<DOCUMENT>
<TYPE>		EX-101.LAB
<SEQUENCE>	4
<FILENAME>	iova-20240304_lab.xml
<DESCRIPTION>	XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
       Show <XBRL>: 194 lines (widest: 316 characters) - 34K bytes  
</TEXT>
</DOCUMENT>

<DOCUMENT>
<TYPE>		EX-101.PRE
<SEQUENCE>	5
<FILENAME>	iova-20240304_pre.xml
<DESCRIPTION>	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
       Show <XBRL>: 128 lines (widest: 316 characters) - 22K bytes  
</TEXT>
</DOCUMENT>

<DOCUMENT>
<TYPE>		GRAPHIC
<SEQUENCE>	6  ⇐ Not a Document/Exhibit
<FILENAME>	tm247846d1_ex99-1img001.jpg
<DESCRIPTION>	GRAPHIC
<TEXT>
       Show <TEXT>: 308 lines (Unix-to-Unix encoding) - 19K bytes  
</TEXT>
</DOCUMENT>

<DOCUMENT>
<TYPE>		XML
<SEQUENCE>	7  ⇐ Document/Exhibit 6
<FILENAME>	R1.htm
<DESCRIPTION>	IDEA: XBRL DOCUMENT
<TEXT>
<html>
       Show <HTML>: 839 lines (widest: 387 characters) - 39K bytes  
</TEXT>
</DOCUMENT>

<DOCUMENT>
<TYPE>		EXCEL
<SEQUENCE>	9  ⇒ 8  ⇐ Document/Exhibit 7
<FILENAME>	Financial_Report.xlsx
<DESCRIPTION>	IDEA: XBRL DOCUMENT
<TEXT>
       Show <TEXT>: 131 lines (Unix-to-Unix encoding) - 8K bytes  
</TEXT>
</DOCUMENT>

<DOCUMENT>
<TYPE>		XML
<SEQUENCE>	10  ⇒ 9  ⇐ Not a Document/Exhibit
<FILENAME>	Show.js
<DESCRIPTION>	IDEA: XBRL DOCUMENT
<TEXT>
       Show <TEXT>: 5 lines (widest: 296 characters) - 973 bytes  
</TEXT>
</DOCUMENT>

<DOCUMENT>
<TYPE>		XML
<SEQUENCE>	11  ⇒ 10  ⇐ Not a Document/Exhibit
<FILENAME>	report.css
<DESCRIPTION>	IDEA: XBRL DOCUMENT
<TEXT>
       Show <TEXT>: 182 lines (widest: 57 characters) - 4K bytes  
</TEXT>
</DOCUMENT>

<DOCUMENT>
<TYPE>		XML
<SEQUENCE>	13  ⇒ 11  ⇐ Document/Exhibit 8
<FILENAME>	FilingSummary.xml
<DESCRIPTION>	IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
       Show <XML>: 48 lines (widest: 110 characters) - 2K bytes  
</TEXT>
</DOCUMENT>

<DOCUMENT>
<TYPE>		JSON
<SEQUENCE>	15  ⇒ 12  ⇐ Document/Exhibit 9
<FILENAME>	MetaLinks.json
<DESCRIPTION>	IDEA: XBRL DOCUMENT
<TEXT>
       Show <TEXT>: 1,343 lines (widest: 520 characters) - 39K bytes  
</TEXT>
</DOCUMENT>

<DOCUMENT>
<TYPE>		ZIP
<SEQUENCE>	16  ⇒ 13  ⇐ Document/Exhibit 10
<FILENAME>	0001104659-24-030249-xbrl.zip
<DESCRIPTION>	IDEA: XBRL DOCUMENT
<TEXT>
       Show <TEXT>: 328 lines (Unix-to-Unix encoding) - 20K bytes  
</TEXT>
</DOCUMENT>

<DOCUMENT>
<TYPE>		XML
<SEQUENCE>	17  ⇒ 14  ⇐ Document/Exhibit 11
<FILENAME>	tm247846d1_8k_htm.xml
<DESCRIPTION>	IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
       Show <XML>: 59 lines (widest: 136 characters) - 4K bytes  
</TEXT>
</DOCUMENT>

</SUBMISSION>

↑Top

Filing Submission 0001104659-24-030249 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Iovance Biotherapeutics, Inc. – ‘8-K’ for 3/4/24

On: Monday, 3/4/24, at 8:00am ET · For: 3/4/24 · Accession #: 1104659-24-30249 · File #: 1-36860

Previous ‘8-K’: ‘8-K’ on 2/29/24 for 2/28/24 · Next: ‘8-K’ on 3/29/24 for 3/26/24 · Latest: ‘8-K’ on / for 5/9/24

Current Report — Form 8-KFiling Table of Contents

Current Report — Form 8-K

Filing Table of Contents